In patients with episodic flushing, watery diarrhea, abdominal cramping, wheezing, or right‑sided valvular heart disease, how should carcinoid syndrome be screened and what is the first‑line test?

Screening for Carcinoid Syndrome

In patients presenting with episodic flushing, watery diarrhea, abdominal cramping, wheezing, or right-sided valvular heart disease, the first-line screening test is a 24-hour urine collection for 5-hydroxyindoleacetic acid (5-HIAA). 1

Biochemical Screening Approach

The 24-hour urine 5-HIAA is the gold standard biochemical test for carcinoid syndrome, particularly when symptoms suggest hormone hypersecretion 1. This test measures the metabolic breakdown product of serotonin and is generally recommended in patients with metastatic lung or gastrointestinal carcinoid tumors, especially when classic symptoms of flushing and diarrhea are present 1.

Serum chromogranin A should be measured concurrently as an additional biomarker, though it is less specific than 5-HIAA 2. Elevated chromogranin A levels (>100 ng/mL) support the diagnosis but can be elevated in other conditions.

Critical Clinical Context

The classic carcinoid syndrome typically occurs in only 8-28% of patients with neuroendocrine tumors and is usually not observed unless liver metastases or retroperitoneal disease are present 1. This is because metabolic products from intestinal NETs are rapidly destroyed by liver enzymes in the portal circulation; only when hepatic metastases release these products directly into systemic circulation via hepatic veins do symptoms manifest 1.

Cardiac Screening Protocol

When carcinoid syndrome is present or 5-HIAA levels are elevated, annual echocardiography screening for carcinoid heart disease is mandatory 3. This is critical because:

• 50-66% of patients with carcinoid syndrome develop valvular cardiac complications 1
• Carcinoid heart disease typically causes tricuspid regurgitation and/or pulmonary stenosis with characteristic thickened, retracted, and immobile leaflets 2, 4
• Early detection and intervention prolong survival 5

The threshold of 5-HIAA elevation associated with carcinoid heart disease risk is well-established, with levels >108 mg/24 hours (SI: >565 µmol/24 hours) indicating particularly high risk 2.

Imaging Evaluation

Once biochemical screening suggests carcinoid syndrome, proceed with:

• Multiphase CT or MRI to assess disease burden and locate the primary tumor (NETs are highly vascular and can appear isodense with liver on conventional CT) 1
• Somatostatin receptor scintigraphy using [111In-DTPA]-octreotide, as most NETs express high-affinity somatostatin receptors 1
• Chest CT to assess for lung metastases 1

Common Pitfalls to Avoid

1. Do not rely on symptoms alone: Patients may present with atypical manifestations such as isolated severe tricuspid regurgitation without classic flushing 2, or with electrolyte derangements dominating the clinical picture 2

2. Consider carcinoid syndrome even with isolated right-sided valvulopathy: Chronic diarrhea with isolated right-sided valve disease should prompt evaluation even when other symptoms are absent 2

3. Screen for Cushing's syndrome in bronchopulmonary/thymic NETs: These tumors are associated with ACTH production and require specific workup if hypercortisolemia is suspected 1

4. Recognize that left-sided valve involvement is rare but can occur with bronchopulmonary carcinoid, right-to-left shunting, or markedly elevated circulating vasoactive substances 4